CU20160182A7 - Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido - Google Patents
Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentidoInfo
- Publication number
- CU20160182A7 CU20160182A7 CUP2016000182A CU20160182A CU20160182A7 CU 20160182 A7 CU20160182 A7 CU 20160182A7 CU P2016000182 A CUP2016000182 A CU P2016000182A CU 20160182 A CU20160182 A CU 20160182A CU 20160182 A7 CU20160182 A7 CU 20160182A7
- Authority
- CU
- Cuba
- Prior art keywords
- naftiridine
- diona
- assets
- compounds derived
- sense
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title 1
- 108020004485 Nonsense Codon Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000037434 nonsense mutation Effects 0.000 abstract 2
- KVOHQTLDEXUTGJ-UHFFFAOYSA-N 1,6-naphthyridine-2,3-dione Chemical compound O=C1C(N=C2C=CN=CC2=C1)=O KVOHQTLDEXUTGJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención se refiere a compuestos derivados de 1,6-naftiridina-diona de fórmula (I'): ESPACIO PARA FÓRMULA o a una sal del mismo, activos como supresores de mutación sin sentido, en donde los sustituyentes son como se definen en el Capítulo Descriptivo; a su preparación, a su uso como un medicamento, y a los medicamentos que lo comprenden. La ventaja de los compuestos de la invención es que promueven la lectura de traducción teniendo valores de AC50 para la supresión de la mutación sin sentido entre 0,4 y 22 uM.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170976 | 2014-06-03 | ||
| PCT/IB2015/054174 WO2015186063A1 (en) | 2014-06-03 | 2015-06-02 | Naphthyridinedione derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160182A7 true CU20160182A7 (es) | 2017-03-03 |
| CU24438B1 CU24438B1 (es) | 2019-09-04 |
Family
ID=50841689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000182A CU24438B1 (es) | 2014-06-03 | 2015-06-02 | Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10138232B2 (es) |
| EP (1) | EP3152209B1 (es) |
| JP (2) | JP6343034B2 (es) |
| KR (1) | KR101905295B1 (es) |
| CN (1) | CN106459043B (es) |
| AP (1) | AP2016009545A0 (es) |
| AR (1) | AR100706A1 (es) |
| AU (2) | AU2015270125B2 (es) |
| BR (1) | BR112016027383A8 (es) |
| CA (1) | CA2950724A1 (es) |
| CL (1) | CL2016003081A1 (es) |
| CR (1) | CR20160565A (es) |
| CU (1) | CU24438B1 (es) |
| EA (1) | EA030374B1 (es) |
| EC (1) | ECSP16096831A (es) |
| ES (1) | ES2731802T3 (es) |
| GT (1) | GT201600252A (es) |
| IL (1) | IL248773B (es) |
| MX (1) | MX374245B (es) |
| MY (1) | MY178379A (es) |
| PE (1) | PE20170086A1 (es) |
| PH (2) | PH12016502293A1 (es) |
| SG (1) | SG11201609209YA (es) |
| SV (1) | SV2016005331A (es) |
| TN (1) | TN2016000490A1 (es) |
| TW (1) | TWI688565B (es) |
| UY (1) | UY36150A (es) |
| WO (1) | WO2015186063A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2743183T3 (es) | 2014-06-03 | 2020-02-18 | Novartis Ag | Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras |
| ES2731802T3 (es) | 2014-06-03 | 2019-11-19 | Novartis Ag | Derivados de naftiridinodiona como supresores de mutaciones sin sentido |
| WO2015186062A1 (en) * | 2014-06-03 | 2015-12-10 | Novartis Ag | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES |
| WO2019225625A1 (ja) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
| WO2020022375A1 (ja) | 2018-07-24 | 2020-01-30 | ソニーセミコンダクタソリューションズ株式会社 | 半導体装置 |
| WO2024161623A1 (ja) * | 2023-02-03 | 2024-08-08 | 株式会社 RINAT Imaging | リードスルー薬、リードスルー用組み合わせ剤及び核酸プローブの使用 |
| CN117756607A (zh) * | 2023-12-01 | 2024-03-26 | 陕西煤业化工技术研究院有限责任公司 | 一种二甲酚馏分异构化生产高值二甲酚的工艺及系统 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| JP2989871B2 (ja) * | 1989-08-30 | 1999-12-13 | 大日本製薬株式会社 | 三環式化合物 |
| DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| WO1996028444A1 (en) | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
| US6016875A (en) * | 1998-02-10 | 2000-01-25 | Case Corporation | Gain adaptation control for hydraulic systems |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP3345895B1 (en) | 2003-04-11 | 2019-12-04 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| MX341797B (es) * | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN101076703A (zh) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | 用于无义抑制的化合物及其使用方法 |
| LT2390255T (lt) | 2006-04-03 | 2016-10-25 | Technion Research & Development Foundation Ltd. | Nauji aminoglikozidai ir jų panaudojimas genetinių sutrikimų gydyme |
| CN101563349A (zh) | 2006-08-23 | 2009-10-21 | 神经能质公司 | 经卤烷基取代的嘧啶酮衍生物 |
| HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| WO2012016930A1 (en) | 2010-08-05 | 2012-02-09 | Universite De Droit Et Sante De Lille | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound |
| CN107569487A (zh) | 2012-12-13 | 2018-01-12 | 诺华股份有限公司 | 作为无义突变抑制子的嘧啶并[4,5‑b]喹啉‑4,5(3H,10H)‑二酮 |
| ES2743183T3 (es) | 2014-06-03 | 2020-02-18 | Novartis Ag | Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras |
| ES2731802T3 (es) | 2014-06-03 | 2019-11-19 | Novartis Ag | Derivados de naftiridinodiona como supresores de mutaciones sin sentido |
| WO2015186062A1 (en) | 2014-06-03 | 2015-12-10 | Novartis Ag | PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES |
-
2015
- 2015-06-02 ES ES15731121T patent/ES2731802T3/es active Active
- 2015-06-02 AU AU2015270125A patent/AU2015270125B2/en not_active Ceased
- 2015-06-02 SG SG11201609209YA patent/SG11201609209YA/en unknown
- 2015-06-02 CA CA2950724A patent/CA2950724A1/en not_active Abandoned
- 2015-06-02 CN CN201580029417.3A patent/CN106459043B/zh not_active Expired - Fee Related
- 2015-06-02 AP AP2016009545A patent/AP2016009545A0/en unknown
- 2015-06-02 TW TW104117848A patent/TWI688565B/zh not_active IP Right Cessation
- 2015-06-02 CU CU2016000182A patent/CU24438B1/es unknown
- 2015-06-02 AR ARP150101737A patent/AR100706A1/es unknown
- 2015-06-02 MY MYPI2016704068A patent/MY178379A/en unknown
- 2015-06-02 BR BR112016027383A patent/BR112016027383A8/pt active Search and Examination
- 2015-06-02 KR KR1020167033550A patent/KR101905295B1/ko not_active Expired - Fee Related
- 2015-06-02 EA EA201692270A patent/EA030374B1/ru not_active IP Right Cessation
- 2015-06-02 MX MX2016015856A patent/MX374245B/es active IP Right Grant
- 2015-06-02 US US14/728,613 patent/US10138232B2/en active Active
- 2015-06-02 TN TN2016000490A patent/TN2016000490A1/en unknown
- 2015-06-02 EP EP15731121.8A patent/EP3152209B1/en active Active
- 2015-06-02 WO PCT/IB2015/054174 patent/WO2015186063A1/en not_active Ceased
- 2015-06-02 JP JP2016570886A patent/JP6343034B2/ja not_active Expired - Fee Related
- 2015-06-02 PE PE2016002514A patent/PE20170086A1/es unknown
- 2015-06-02 CR CR20160565A patent/CR20160565A/es unknown
- 2015-06-03 UY UY0001036150A patent/UY36150A/es not_active Application Discontinuation
-
2016
- 2016-11-06 IL IL248773A patent/IL248773B/en active IP Right Grant
- 2016-11-17 PH PH12016502293A patent/PH12016502293A1/en unknown
- 2016-11-30 CL CL2016003081A patent/CL2016003081A1/es unknown
- 2016-12-02 GT GT201600252A patent/GT201600252A/es unknown
- 2016-12-02 SV SV2016005331A patent/SV2016005331A/es unknown
- 2016-12-28 EC ECIEPI201696831A patent/ECSP16096831A/es unknown
-
2018
- 2018-01-18 AU AU2018200421A patent/AU2018200421A1/en not_active Withdrawn
- 2018-05-17 JP JP2018095248A patent/JP2018138609A/ja active Pending
- 2018-08-13 PH PH12018501709A patent/PH12018501709A1/en unknown
- 2018-10-10 US US16/156,447 patent/US20190248784A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20160182A7 (es) | Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| CU20150061A7 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| CO7101239A2 (es) | Composiciones derivadas de la quitosana | |
| GT201500247A (es) | Imidazopiridazinas sustituidas | |
| EA201791219A1 (ru) | Антибактериальные композиции, имеющие широкий спектр активности | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
| AR101806A1 (es) | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio | |
| EA201890828A1 (ru) | Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин | |
| SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. |